10 April 2026
Efferon at ISICEM

As the ISICEM comes to a close, we would like to thank everyone who took the time to connect with us.
It was a pleasure to engage with so many dedicated professionals. We are encouraged by the strong interest in Efferon technologies, and in particular, the remarkable attention around EfferonNEO.
We believe that next-generation extracorporeal therapies play a key role in critical care. At Efferon, we are committed not only to technological innovation but also to robust scientific validation.
The effectiveness of Efferon NEO is supported by a large, multicenter clinical trial, reflecting our commitment to generating high-quality evidence.
We look forward to sharing more updates and results with you very soon.
Thank you again, and see you at future events!
More news
- Efferon®NEO Receives CE MDR Mark22 April 2026
- Efferon first distributors meeting08 April 2026
- Efferon is now available in Poland11 March 2026
- Efferon®LPS is available in Costa Rica26 February 2026
- Efferon®LPS is now approved in Thailand18 February 2026
- Efferon LPS® incorporated into clinical guidelines of the German Society of Nephrology for therapeutic apheresis10 December 2025
- We’ll see each other in Greece25 November 2025
- Efferon therapies are now available in Armenia!05 November 2025
- Clinical data confirmed the effectiveness of Efferon NEO in children with sepsis30 October 2025
- Efferon LPS has been approved in the Kingdom of Saudi Arabia.18 October 2025
- Extracorporeal removal of antibiotic drugs during Efferon LPS hemoadsorption is predictable and manageable09 October 2025
- Efferon at the 6th Asia Pacific AKI CRRT Congress in Bangkok05 October 2025
- Win a New iPad! Join the Efferon LPS Photo Challenge on LinkedIn12 September 2025
- Efferon LPS hemoadsorption device has been granted regulatory approval in the United Kingdom and Croatia.23 July 2025
- Efferon LPS Now Available in Italy01 July 2025
- Applying Vicenza’s Lessons28 June 2025
- Efferon Expands Its Global Presence23 June 2025
- Efferon expands to new markets with Bertossi partnership06 June 2025
- Efferon LPS becomes available in Romania.25 May 2025
- New distribution agreements in European countries22 July 2024
- Efferon LPS receives CE mark under EU MDR29 April 2024
- Results of LASSO mRCT are published in Shock20 April 2023
- Efferon at LIVES 2022 in Paris03 November 2022
- Efferon has participated in MEDICA30 November 2021
- LASSO multicenter randomized trial launched29 April 2021